Clinical trial
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and…
NCT00415857 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00415857 |
|---|---|
| Title | Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R) |
| Official title | Potential of Immunotherapy to Convert a Complete Cytogenetic Remission in Chronic Myelogenous Leukemia to a Molecular Complete Remission: Randomized Phase II Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and Peginterferon Alfa-2b… |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | The Vaccine Company Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | Peptide Vaccine (PR1 Peptide), Peginterferon alfa-2b, Imatinib, GM-CSF |
| Enrollment | 5 |
| Start date | Dec 1, 2006 |
| Primary completion | Sep 1, 2013 |
| Completion | Sep 1, 2013 |
| First posted | Dec 25, 2006 |
| Last update posted | Aug 21, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: